About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Division of Hematology
›
top-articles
Division of Hematology
217
(top 1%)
papers
6.3K
(top 1%)
citations
42
(top 1%)
h
-index
75
(top 1%)
g
-index
223
all documents
6.6K
doc citations
1.2K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
American Journal of Medicine
2004
415
2
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Annals of Oncology
2010
386
3
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
Leukemia
2010
321
4
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Haematologica
2008
241
5
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Blood
2009
229
6
Splenic marginal zone lymphoma: a prognostic model for clinical use
Blood
2006
217
7
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Blood
2008
192
8
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
Blood
2011
173
9
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
Blood
2010
153
10
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
Leukemia
2010
135
11
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles
Cancer
2004
121
12
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
Cancer
2014
116
13
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Annals of Oncology
2007
111
14
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection
Leukemia
2012
98
15
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia
Cancer
2012
97
16
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
Blood
2013
96
17
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity
Haematologica
2006
95
18
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma
Haematologica
2010
91
19
Immune-mediated neuropathies in myeloma patients treated with bortezomib
Clinical Neurophysiology
2008
88
20
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy
Annals of Oncology
2006
85
21
Leukemic transformation of polycythemia vera
Cancer
2005
79
22
Clinical relevance of JAK2 (V617F) mutant allele burden
Haematologica
2009
78
23
Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients
Leukemia Research
2010
75
24
Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution
Leukemia
2005
72
25
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia
Haematologica
2003
68
26
Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone
Annals of Hematology
2004
64
27
Nongastric Marginal‐Zone B‐Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Oncologist
2006
63
28
Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients
Leukemia
2003
61
29
Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma
Cancer
2005
61
30
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
British Journal of Haematology
2021
56
31
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma
British Journal of Haematology
2002
54
32
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
Blood
2015
53
33
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patients
Cancer
1993
52
34
Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation as a Late Complication of Chronic Graft-versus-Host Disease
Transplantation
2006
51
35
Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders
Leukemia
2004
50
36
Risk of second cancers in Waldenström macroglobulinemia
Annals of Oncology
2012
50
37
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients
American Journal of Hematology
2012
49
38
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood
2022
49
39
Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity
Haematologica
2000
49
40
HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry
Bone Marrow Transplantation
2009
48
41
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease
European Journal of Haematology
2009
47
42
Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT
Annals of Oncology
2010
46
43
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Oncotarget
2011
44
44
CpG Oligonucleotide Combined with Interleukin-2 Reveals Unexpected Chromosomal Lesions In B-CLL
Blood
2010
44
45
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Annals of Oncology
2008
40
46
FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells
Cell Reports
2014
39
47
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk
Supportive Care in Cancer
2019
38
48
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
British Journal of Haematology
2002
36
49
Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma
Journal of Clinical Oncology
2007
36
50
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea
Leukemia
2002
35
site/software ©
exaly
; All materials licenced under
CC by-SA
.